← Back to Analyst Consensus 
ANTX Buy
AN2 Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 8
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 5, 2026 (10 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Jul 20, 2026 | Guggenheim | initiate | — → Buy | — | 52% |
| May 14, 2026 | Leerink Partners | upgrade | Market Perform → Outperform | — | 51% |
| May 5, 2025 | JMP Securities | maintain | Market Outperform → Market Outperform | $2 | 53% |
| Mar 26, 2025 | Citizens Capital Markets | reiterate | Market Outperform → Market Outperform | $5 | 49% |
| Feb 25, 2025 | Citizens Capital Markets | reiterate | Market Outperform → Market Outperform | $5 | 49% |
| Feb 3, 2025 | JMP Securities | reiterate | Market Outperform → Market Outperform | $5 | 53% |
| Nov 19, 2024 | JMP Securities | reiterate | Market Outperform → Market Outperform | $5 | 53% |
| Nov 18, 2024 | TD Cowen | downgrade | Buy → Hold | $0 | 54% |
| Aug 9, 2024 | JMP Securities | maintain | Market Outperform → Market Outperform | $3 | 53% |
| Jul 3, 2024 | Leerink Partners | upgrade | Market Perform → Outperform | $0 | 51% |
| May 16, 2024 | Evercore ISI Group | maintain | In-Line → In-Line | $2 | 58% |
| Apr 2, 2024 | JMP Securities | upgrade | Market Perform → Market Outperform | $6 | 53% |
| Apr 1, 2024 | Oppenheimer | reiterate | Perform → Perform | $0 | 52% |
| Feb 13, 2024 | Leerink Partners | downgrade | Outperform → Market Perform | $7 | 51% |
| Feb 12, 2024 | Evercore ISI Group | downgrade | Outperform → In-Line | $7 | 58% |
| Feb 12, 2024 | Oppenheimer | downgrade | Outperform → Perform | $0 | 52% |
| Feb 12, 2024 | JMP Securities | downgrade | Market Outperform → Market Perform | $0 | 53% |
| Jan 4, 2024 | JMP Securities | initiate | — → Market Outperform | $30 | 53% |
| Mar 30, 2023 | Oppenheimer | maintain | — → Outperform | $24 | 52% |
| Nov 14, 2022 | SVB Leerink | maintain | — → Outperform | $25 | — |
| Apr 19, 2022 | Evercore ISI Group | initiate | — → Outperform | $25 | 58% |
| Apr 19, 2022 | Oppenheimer | initiate | — → Outperform | $22 | 52% |
| Apr 19, 2022 | Cowen & Co. | initiate | — → Outperform | $0 | — |
Price Target Trend
Apr 11, 2026 Oct 26, 2026
EPS Estimates
0y —
0q —
+1y —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days